GSK updates total voting rights for May 2026

GSK plc reported its total voting rights as of 31 May 2026.

Rhea-AI Filing Summary

GSK plc reported its total voting rights as of 31 May 2026. The company’s issued share capital consisted of 4,316,224,814 ordinary shares of 31 ¼ pence each, of which 265,968,706 were held in treasury. This leaves 4,050,256,108 voting rights currently in issue.

Shareholders can use this voting rights figure as the denominator when calculating whether they must notify the company and regulators about their shareholdings or changes in their interests under the UK Financial Conduct Authority’s disclosure rules.

Key Figures

Ordinary shares issued: 4,316,224,814 shares Treasury shares: 265,968,706 shares Total voting rights: 4,050,256,108 +1 more

4 metrics

Ordinary shares issued 4,316,224,814 shares Issued share capital as of 31 May 2026

Treasury shares 265,968,706 shares Held in treasury as of 31 May 2026

Total voting rights 4,050,256,108 Voting rights in issue as of 31 May 2026

Nominal value per share 31 ¼ pence Ordinary share nominal value

Key Terms

Total Voting Rights, Treasury, Disclosure Guidance and Transparency Rule 5.6.1R, ordinary shares

4 terms

Total Voting Rights financial

"Total Voting Rights In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R"

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

Treasury financial

"of which 265,968,706 Ordinary Shares were held in Treasury."

The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.

Disclosure Guidance and Transparency Rule 5.6.1R regulatory

"In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R"

ordinary shares financial

"consisted of 4,316,224,814 shares of 31 ¼ pence each ('Ordinary Shares')"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What total voting rights did GSK (GSK) report as of 31 May 2026?

GSK reported a total of 4,050,256,108 voting rights as of 31 May 2026. Investors use this number as the denominator when assessing whether their holdings trigger disclosure thresholds under UK transparency rules.

How many GSK (GSK) shares were in issue and in treasury at 31 May 2026?

GSK had 4,316,224,814 ordinary shares in issue at 31 May 2026, each with a nominal value of 31 ¼ pence. Of these, 265,968,706 shares were held in treasury and therefore do not carry voting rights.

Why does GSK (GSK) publish a total voting rights figure?

GSK publishes its total voting rights figure to help shareholders comply with UK Financial Conduct Authority disclosure rules. Investors must use this number to determine if they need to notify changes in their shareholdings.

Which regulatory rules apply to GSK’s (GSK) voting rights disclosure?

The disclosure follows the UK FCA’s Disclosure Guidance and Transparency Rule 5.6.1R. This rule requires listed companies to notify the market of their total voting rights so investors can assess their reporting obligations.

What type of shares make up GSK’s (GSK) issued share capital?

GSK’s issued share capital at 31 May 2026 comprised ordinary shares of 31 ¼ pence each. These ordinary shares represent the company’s equity base, although shares held in treasury do not carry voting rights.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 10:46 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 1 June 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 May 2026 consisted of 4,316,224,814 shares of 31 ¼ pence each ('Ordinary Shares'), of which 265,968,706 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,050,256,108. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 June 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: June 01, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc